Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Rapid Dose Therapeutics Corp C.DOSE

Alternate Symbol(s):  RDTCF

Rapid Dose Therapeutics Corp. is a Canadian biotechnology company. It provides disruptive drug delivery technologies designed to improve patient outcomes. Its flagship product, QuickStrip, is a thin, orally dissolvable film that can be infused with an infinite list of active ingredients, including nutraceuticals, pharmaceuticals, and vaccines, that are delivered quickly into the bloodstream, resulting in rapid onset of the active ingredient. It has one operating segment comprising production, distribution, research, and the provision of technical services for the delivery of oral thin film strips containing active ingredients. It offers over-the-counter and pharmaceutical drug delivery solutions. Its QuickStrip Energy delivers energizing caffeine. Its QuickStrip B12 delivers vitamin B12 to the system, assisting with metabolism and physical energy. Its QuickStrip Sleep delivers melatonin to the system, inducing natural and healthy sleep. QuickStrip Lidocaine is its dental product.


CSE:DOSE - Post by User

Comment by lscfaon Mar 17, 2023 4:18pm
98 Views
Post# 35345960

RE:RE:Where is an update from the company

RE:RE:Where is an update from the company

 

It took over 4 months for Personas to get reinstated..... 

 On October 4, 2022, the Company [Personas] made an application to the OSC for a full revocation of the CTO (the "Application"). The Application is currently under review and the Company is working with the OSC to obtain this order. There is no guarantee or assurance that the CTO will be partially and/or fully revoked, but if obtained, then the Company plans to apply to the TSX Venture Exchange for reinstatement of trading, notwithstanding, there is no guarantee or assurance that the full revocation of the CTO and/or reinstatement or trading will be completed.

The TSX Venture Exchange has also issued a reinstatement of trading. Trading of the company's stock will resume on the TSX Venture Exchange on Feb. 14, 2023.

<< Previous
Bullboard Posts
Next >>